MIST - Milestone Pharmaceuticals Inc. News

Milestone Pharmaceuticals Presenting Data In Moderated EPoster Session Titled 'he Impact of PSVT on

Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the developme

Milestone Pharmaceuticals Announces Data Presented at ESC Congress 2026 on the Impact of Paroxysmal

MONTREAL and CHARLOTTE, N.C., Aug. 27, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nas

Milestone Pharmaceuticals Initiates Pivotal Phase 3 Trial of Etripamil Nasal Spray for Self-Administ

ReVeRA-301 Trial is Evaluating the Same 70 mg Repeat-Dose Regimen that is FDA Approved for Paroxysma

This Sphere Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For

Top Wall Street analysts updated ratings on SPHR, CVLG, MIST, MSGE,. Check out analyst ratings page

Cantor Fitzgerald Initiates Coverage On Milestone Pharmaceuticals with Overweight Rating, Announces

Cantor Fitzgerald analyst Olivia Brayer Saunders initiates coverage on Milestone Pharmaceuticals

Milestone Pharmaceuticals: Reiterating Sell As The Losses Compound

Milestone Pharmaceuticals remains a 'Sell' due to weak CARDAMYST differentiation and poor commercial

Milestone Pharmaceuticals Inc. (MIST) Q2 2026 Earnings Call Transcript

marketbeat.com

Milestone Pharmaceuticals Q2 Earnings Call Highlights

Milestone Pharmaceuticals NASDAQ: MIST reported early commercial traction for CARDAMYST following it

zacks.com

Milestone Pharmaceuticals (MIST) Reports Q2 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.21 per share versus the Zacks

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Gainers Bone Biologics (NASDAQ:BBLG) stock moved upwards by 17.7% to $1.07 during Wednesday's p

Milestone Pharmaceuticals Announces Second Quarter 2026 Financial Results and Provides Corporate Upd

Over 50% of commercially insured lives in the U.S., representing a recent and significant increase,

Milestone Pharmaceuticals Q2 EPS $(0.21) Misses $(0.20) Estimate, Sales $559.000K Miss $816.667K Est

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.21) per share which missed

Milestone Pharmaceuticals to Announce Second Quarter 2026 Financial Results on August 12, 2026

MONTREAL and CHARLOTTE, N.C., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nas

zacks.com

After Plunging 20.2% in 4 Weeks, Here's Why the Trend Might Reverse for Milestone Pharmaceuticals (M

Milestone Pharmaceuticals (MIST) has become technically an oversold stock now, which implies exhaust

12 Health Care Stocks Moving In Tuesday's After-Market Session

Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MONTREAL and CHARLOTTE, N. C. , July 02, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (Na

gurufocus.com

Alpha Cognition Announces Election of Dr. Robert Wills as Chairman of the Board

Alpha Cognition Inc. (Nasdaq: ACOG) (âAlpha Cognitionâ, or the âCompanyâ), a biopharmaceutic

Milestone Pharmaceuticals Inc. (MIST) Shareholder/Analyst Call Prepared Remarks Transcript

Milestone Pharmaceuticals: Here Comes The Revenue Ramp

Milestone Pharmaceuticals Inc. remains a Strong Buy, despite recent volatility and a 37% stock decli

Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Lowers Price Target to $7

Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overwei

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conferenc

MONTREAL and CHARLOTTE, N.C., May 14, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasd

fool.com

Why Milestone Pharmaceuticals Stock Wilted on Wednesday

The biotech fell well short of analyst projections in the first quarter.

marketbeat.com

Milestone Pharmaceuticals Q1 Earnings Call Highlights

Milestone Pharmaceuticals NASDAQ: MIST said its first quarter of 2026 marked the beginning of commer

Milestone Pharmaceuticals Inc. (MIST) Q1 2026 Earnings Call Transcript

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) reported first-quarter earnings on Wednesday before the

Milestone Reports Q1 Results, Highlights Initial CARDAMYST Sales

Milestone Pharmaceuticals Inc. (NASDAQ: MIST) reported first-quarter earnings on Wednesday before th

Milestone Pharmaceuticals Q1 2026 Earnings Call: Complete Transcript

zacks.com

Milestone Pharmaceuticals (MIST) Reports Q1 Loss, Lags Revenue Estimates

Milestone Pharmaceuticals (MIST) came out with a quarterly loss of $0.2 per share versus the Zacks C

12 Health Care Stocks Moving In Wednesday's Pre-Market Session

Milestone Expands CARDAMYST Push Into Europe, China And New AFib Trial

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) a biopharmaceutical company focused on the development

Earnings Scheduled For May 13, 2026

12 Health Care Stocks Moving In Friday's Intraday Session

Why Milestone Pharma Stock Is Taking A Dive Today

EU decision delay for Milestone Pharmaceuticals etripamil, despite strong U.S. launch progress, soli

Milestone Pharmaceuticals Q4 EPS $(0.16), Inline, Sales $1.546M Beat $1.200M Estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.16) per share which met the

Earnings Scheduled For March 20, 2026

Milestone Pharmaceuticals Gears Up For Q4 Print; Here Are The Recent Forecast Changes From Wall Stre

Earnings report for Milestone Pharmaceuticals Inc. (MIST) expected on March 19. Analysts predict 16

Milestone Pharmaceuticals Announces Availability Of Cardamyst (Etripamil) Nasal Spray, Its First Co

CARDAMYST is a prescription medication indicated for the conversion of acute symptomatic episodes of

HC Wainwright & Co. Reiterates Buy on Milestone Pharmaceuticals, Maintains $8 Price Target

HC Wainwright & Co. analyst Brandon Folkes reiterates Milestone Pharmaceuticals (NASDAQ:MIST)

12 Health Care Stocks Moving In Tuesday's After-Market Session

AptarGroup Announces That Its Bidose Liquid Nasal Spray System Liquid Is The Mechanism For Deliver

Aptar Group, Inc. (NYSE:ATR), a global leader in drug and consumer product dosing, dispensing and pr

Wells Fargo Maintains Overweight on Milestone Pharmaceuticals, Raises Price Target to $8

Wells Fargo analyst Mohit Bansal maintains Milestone Pharmaceuticals (NASDAQ:MIST) with a Overwei

TD Cowen Upgrades Milestone Pharmaceuticals to Buy, Announces $8 Price Target

TD Cowen analyst Ritu Baral upgrades Milestone Pharmaceuticals (NASDAQ:MIST) from Hold to Buy and

HC Wainwright & Co. Maintains Buy on Milestone Pharmaceuticals, Raises Price Target to $8

HC Wainwright & Co. analyst Brandon Folkes maintains Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats

The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in

Market-Moving News for December 15th

RADX: 471% | Radiopharm Theranostics' Interim Data From The First Twelve Patients In Its U.S. Ph

Reported Friday, Milestone Wins FDA Approval For CARDAMYST, First Self-Administered Nasal Spray For

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal sp

12 Health Care Stocks Moving In Friday's Intraday Session

Milestone Pharmaceuticals Q3 EPS $(0.12) Beats $(0.16) Estimate

Milestone Pharmaceuticals (NASDAQ:MIST) reported quarterly losses of $(0.12) per share which beat th

Milestone Pharma Says New Data Analyses Of Investigational Product For PSVT, Etripamil Nasal Spray,

Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the developmen